MRI Agents for Disease Detection

The aim of this project is to develop new magnetic resonance (MR) molecular imaging strategies that will enable the in vivo monitoring of biological processes. Specifically we shall develop novel polymers for imaging of early markers of diseases such as melanoma, prostate cancer, malignant glioma and Alzheimer’s disease. Specifically the project involves the synthesis of new partly-fluorinated polymers having controlled architecture for the rapidly developing field of 19F MRI. The project aims to relate the structure of the macromolecules, determined carefully using advanced techniques such as NMR, light scattering, GPC, AFM and electron microscopy, to the performance as imaging agents. The agents will be tested in small animal (mouse) models of disease already developed by this group and our collaborators. Responsible scientist: Andrew Whittaker, Hui Peng and Cheng Zhang